Longeveron (LGVN) Gross Profit Growth (3y) (2023 - 2026)
Longeveron (LGVN) Gross Profit Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 9.20% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.09% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 77.42% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 28.75% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 45.27% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 59.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -45.72% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 80.79% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 25.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.08% |
| Mar 31, 2026 | 51.45% |
| Dec 31, 2025 | 88.26% |
| Sep 30, 2025 | 10.76% |
| Jun 30, 2025 | -3.01% |
| Mar 31, 2025 | 18.56% |
| Dec 31, 2024 | 97.31% |
| Sep 30, 2024 | 60.81% |
| Jun 30, 2024 | 18.26% |
| Mar 31, 2024 | 30.22% |
| Dec 31, 2023 | -26.07% |
| Sep 30, 2023 | -47.49% |
| Jun 30, 2023 | -6.01% |
| Mar 31, 2023 | -54.60% |